Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2026,
GSK paid$424 Mil more to buy back shares than it received from issuing new shares.
It received$1,576 Mil from issuing more debt.
It paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spent$857 Mil paying cash dividends to shareholders.
It received$139 Mil on other financial activities.
In all, GSKearned$433 Mil on financial activities for the
three
months ended in Mar. 2026.
GSK (OTCPK:GLAXF) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
GSK's issuance of stock for the
three
months ended in Mar. 2026 was $11 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
GSK's repurchase of stock for the
three
months ended in Mar. 2026 was $-435 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
GSK's net issuance of debt for the
three
months ended in Mar. 2026 was $1,576 Mil.
GSK received$1,576 Mil from issuing more debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
GSK's net issuance of preferred for the
three
months ended in Mar. 2026 was $0 Mil.
GSK paid$0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
GSK's cash flow for dividends for the
three
months ended in Mar. 2026 was $-857 Mil.
GSK spent$857 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
GSK's other financing for the
three
months ended in Mar. 2026 was $139 Mil.
GSK received$139 Mil on other financial activities.
GSK Cash Flow from Financing Related Terms
GSK Cash Flow from Financing Historical Data
* Premium members only.
The historical data trend for GSK's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
GSK's Cash from Financing for the fiscal year that ended in Dec. 2025 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5,779 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Financing of $-5,779 Mil mean?
GSK (GLAXF) has a Cash Flow from Financing of $-5,779 Mil as of Mar. 2026. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for GSK and its competitors.
Is GSK's Cash Flow from Financing too high?
GSK's current Cash Flow from Financing is $-5,779 Mil. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Cash Flow from Financing compare to LLY and JNJ?
GSK's Cash Flow from Financing of $-5,779 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Financing for a Drug Manufacturers company?
A good Cash Flow from Financing depends on the Drug Manufacturers industry context. However, Cash Flow from Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Financing mean?
A high Cash Flow from Financing can signal that a stock is expensive relative to its fundamentals. Cash Flow from Financing is the amount of cash earned or paid from financing operations. View historical data for GSK and its competitors. GSK's current Cash Flow from Financing is $-5,779 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $22.07, compared to a current price of $25.77 — trading 16.8% above its estimated fair value. The current Cash Flow from Financing is $-5,779 Mil. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Financing calculated?
Cash Flow from Financing is calculated from a company's financial statements. For GSK (GLAXF), the current Cash Flow from Financing is $-5,779 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GSK (GLAXF) Overvalued in 2026?
Based on GuruFocus' analysis, GSK stock appears to be overvalued.
The current stock price of $25.77 is trading 16.8% above its estimated GF Value™ of $22.07.
GuruFocus considers GSK to be Modestly Overvalued.
Key valuation signals for GLAXF:
Cash Flow from Financing: $-5,779 Mil
GF Value™: $22.07 vs. price of $25.77 (16.8% above fair value)
No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score
Get the complete analysis for GLAXF
Cash Flow from Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLAXF has been successfully added to your 
